91 results
424B5
NTLA
Intellia Therapeutics Inc
26 Feb 24
Prospectus supplement for primary offering
7:04am
of a majority of our directors then in office even if less than a quorum.
No written consent of stockholders. Our second amended and restated certificate … of stockholders. Our bylaws provide that only a majority of the members of our board of directors then in office may call special meetings
424B5
NTLA
Intellia Therapeutics Inc
23 Feb 24
Prospectus supplement for primary offering
5:22pm
of our board, may only be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum.
No written consent … stockholder without holding a meeting of stockholders.
Meetings of stockholders. Our bylaws provide that only a majority of the members of our board
S-3ASR
agfhx ptg5wst52
24 Nov 23
Automatic shelf registration
9:30am
S-3ASR
EX-4.1
14hbj 87cr
24 Nov 23
Automatic shelf registration
9:30am
S-3ASR
EX-4.2
xp4mjy9mfkd 4qmu
24 Nov 23
Automatic shelf registration
9:30am
8-K
EX-99.1
1hshgkdg
9 Nov 23
Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
7:45am
8-K
5ij65b101jytx
2 Nov 23
Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting
7:11am
8-K
EX-99.1
dtmgb
2 Nov 23
Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting
7:11am
8-K
EX-99.1
1hk330plklg0 c6s
3 Aug 23
Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
7:45am
8-K
nvpb7g53pmnj21tndt0f
16 Jun 23
Amendments to Articles of Incorporation or Bylaws
4:13pm
8-K
EX-99.1
l0pz4rd3c
12 Jun 23
Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of
7:00am
8-K
p55ux
12 Jun 23
Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of
7:00am